Prognostic predictive value of urothelial carcinoma of the bladder after TURBT based on multiphase CT radiomics. 2024

Jing Xue, and Zijian Zhuang, and Lin Peng, and Xingchi Chen, and Haitao Zhu, and Dongqing Wang, and Lirong Zhang
Department of Medical Imaging, The Affiliated Hospital of Jiangsu University, Zhenjiang, 212001, Jiangsu, China.

OBJECTIVE To investigate multiphase computed tomography (CT) radiomics-based combined with clinical factors to predict overall survival (OS) in patients with bladder urothelial carcinoma (BLCA) who underwent transurethral resection of bladder tumor (TURBT). METHODS Data were retrospectively collected from 114 patients with primary BLCA from February 2016 to February 2018. The regions of interest (ROIs) of the plain, arterial, and venous phase images were manually segmented. The Cox regression algorithm was used to establish 3 basic models for the plain phase (PP), arterial phase (AP), and venous phase (VP) and 2 combination models (AP + VP and PP + AP + VP). The highest-performing radiomics model was selected to calculate the radiomics score (Rad-score), and independent risk factors affecting patients' OS were analyzed using Cox regression. The Rad-score and clinical risk factors were combined to construct a joint model and draw a visualized nomogram. RESULTS The combined model of PP + AP + VP showed the best performance with the Akaike Information Criterion (AIC) and Consistency Index (C-index) in the test group of 130.48 and 0.779, respectively. A combined model constructed with two independent risk factors (age and Ki-67 expression status) in combination with the Rad-score outperformed the radiomics model alone; AIC and C-index in the test group were 115.74 and 0.840, respectively. The calibration curves showed good agreement between the predicted probabilities of the joint model and the actual (p < 0.05). The decision curve showed that the joint model had good clinical application value within a large range of threshold probabilities. CONCLUSIONS This new model can be used to predict the OS of patients with BLCA who underwent TURBT.

UI MeSH Term Description Entries

Related Publications

Jing Xue, and Zijian Zhuang, and Lin Peng, and Xingchi Chen, and Haitao Zhu, and Dongqing Wang, and Lirong Zhang
January 2022, Frontiers in oncology,
Jing Xue, and Zijian Zhuang, and Lin Peng, and Xingchi Chen, and Haitao Zhu, and Dongqing Wang, and Lirong Zhang
May 2024, The Journal of clinical endocrinology and metabolism,
Jing Xue, and Zijian Zhuang, and Lin Peng, and Xingchi Chen, and Haitao Zhu, and Dongqing Wang, and Lirong Zhang
April 2001, Journal of clinical pathology,
Jing Xue, and Zijian Zhuang, and Lin Peng, and Xingchi Chen, and Haitao Zhu, and Dongqing Wang, and Lirong Zhang
January 2021, Discover. Oncology,
Jing Xue, and Zijian Zhuang, and Lin Peng, and Xingchi Chen, and Haitao Zhu, and Dongqing Wang, and Lirong Zhang
January 2023, Pharmacogenomics and personalized medicine,
Jing Xue, and Zijian Zhuang, and Lin Peng, and Xingchi Chen, and Haitao Zhu, and Dongqing Wang, and Lirong Zhang
November 2016, Oncotarget,
Jing Xue, and Zijian Zhuang, and Lin Peng, and Xingchi Chen, and Haitao Zhu, and Dongqing Wang, and Lirong Zhang
December 2018, Urologic oncology,
Jing Xue, and Zijian Zhuang, and Lin Peng, and Xingchi Chen, and Haitao Zhu, and Dongqing Wang, and Lirong Zhang
November 2021, Journal of clinical medicine,
Jing Xue, and Zijian Zhuang, and Lin Peng, and Xingchi Chen, and Haitao Zhu, and Dongqing Wang, and Lirong Zhang
June 2017, Urologic oncology,
Jing Xue, and Zijian Zhuang, and Lin Peng, and Xingchi Chen, and Haitao Zhu, and Dongqing Wang, and Lirong Zhang
December 2017, Clinical genitourinary cancer,
Copied contents to your clipboard!